Correlation Between Acurx Pharmaceuticals and Reviva Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Acurx Pharmaceuticals and Reviva Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acurx Pharmaceuticals and Reviva Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Acurx Pharmaceuticals LLC and Reviva Pharmaceuticals Holdings, you can compare the effects of market volatilities on Acurx Pharmaceuticals and Reviva Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acurx Pharmaceuticals with a short position of Reviva Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acurx Pharmaceuticals and Reviva Pharmaceuticals.

Diversification Opportunities for Acurx Pharmaceuticals and Reviva Pharmaceuticals

-0.55
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Acurx and Reviva is -0.55. Overlapping area represents the amount of risk that can be diversified away by holding Acurx Pharmaceuticals LLC and Reviva Pharmaceuticals Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Reviva Pharmaceuticals and Acurx Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acurx Pharmaceuticals LLC are associated (or correlated) with Reviva Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Reviva Pharmaceuticals has no effect on the direction of Acurx Pharmaceuticals i.e., Acurx Pharmaceuticals and Reviva Pharmaceuticals go up and down completely randomly.

Pair Corralation between Acurx Pharmaceuticals and Reviva Pharmaceuticals

Given the investment horizon of 90 days Acurx Pharmaceuticals LLC is expected to under-perform the Reviva Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Acurx Pharmaceuticals LLC is 1.5 times less risky than Reviva Pharmaceuticals. The stock trades about -0.21 of its potential returns per unit of risk. The Reviva Pharmaceuticals Holdings is currently generating about 0.19 of returns per unit of risk over similar time horizon. If you would invest  117.00  in Reviva Pharmaceuticals Holdings on September 15, 2024 and sell it today you would earn a total of  144.00  from holding Reviva Pharmaceuticals Holdings or generate 123.08% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Acurx Pharmaceuticals LLC  vs.  Reviva Pharmaceuticals Holding

 Performance 
       Timeline  
Acurx Pharmaceuticals LLC 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Acurx Pharmaceuticals LLC has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unsteady performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.
Reviva Pharmaceuticals 

Risk-Adjusted Performance

14 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Reviva Pharmaceuticals Holdings are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak basic indicators, Reviva Pharmaceuticals demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Acurx Pharmaceuticals and Reviva Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Acurx Pharmaceuticals and Reviva Pharmaceuticals

The main advantage of trading using opposite Acurx Pharmaceuticals and Reviva Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acurx Pharmaceuticals position performs unexpectedly, Reviva Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Reviva Pharmaceuticals will offset losses from the drop in Reviva Pharmaceuticals' long position.
The idea behind Acurx Pharmaceuticals LLC and Reviva Pharmaceuticals Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Other Complementary Tools

Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Equity Valuation
Check real value of public entities based on technical and fundamental data